Could a drug combo shrink bile duct tumors before surgery?
NCT ID NCT05640791
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This trial tests whether giving the immunotherapy drug durvalumab along with chemotherapy before surgery can shrink biliary tract cancers and improve outcomes. About 40 people with resectable tumors will receive the combination, then undergo surgery. The goal is to see if this approach is safe and helps remove the cancer more completely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of durvalumab, gemcitabine, cisplatin, and nab-paclitaxel
- What this could lead to
- If successful, this approach could make surgery more effective for biliary tract cancer by shrinking tumors beforehand, potentially improving survival.
- What could go wrong
- This is a small, early-phase trial with no control group, so results may not confirm benefit. Side effects from the drug combination could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Cancer Hospital Airport Hospital
RECRUITINGTianjin, Tianjin Municipality, 300308, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-••••